Mestinon (Pyridostigmine Bromide)

• Mestinon acts on the cholinergic neuromuscular pathway and is indicated for the following conditions:
• Myasthenia gravis: enhances neuromuscular transmission, leading to increased muscle strength, reduced fatigability, and improved daily functioning in patients with this autoimmune disorder.
• Orthostatic hypotension: augments vascular tone by increasing acetylcholine availability, helping to raise standing blood pressure, diminish orthostatic dizziness, and prevent syncope in affected individuals.
• Myasthenic syndrome associated with thymoma: provides symptomatic relief by improving neuromuscular transmission in patients with thymoma‑related weakness.
• Myasthenia gravis (adjunct therapy): used alongside immunosuppressants to support muscle strength during periods of disease fluctuation.

• Pyridostigmine bromide reversibly inhibits acetylcholinesterase at the neuromuscular junction, preventing the breakdown of acetylcholine. The resulting increase in synaptic acetylcholine prolongs receptor activation, enhancing depolarization of muscle end‑plates and improving transmission of nerve impulses to skeletal muscle fibers. This action restores muscle contractility in conditions where acetylcholine availability is limited. The inhibition is competitive and dose‑dependent, allowing clinicians to titrate effect while maintaining safety.

Pyridostigmine bromide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset that may occur after dosing.
• Diarrhea: increased bowel movements, sometimes watery.
• Abdominal cramps: intermittent stomach pain or cramping.
• Increased salivation: excess drooling or throat wetness.

Serious or Rare Side Effects

• Cholinergic crisis: severe muscle weakness, respiratory difficulty requiring emergency care.
• Severe bradycardia: markedly slowed heart rate that can cause dizziness or fainting.
• Bronchospasm: tightening of airway muscles leading to breathing difficulty.
• Allergic reactions: rash, itching, swelling, or anaphylaxis in rare cases.

When prescribing pyridostigmine bromide, several precautions should be observed to ensure safe use.

• Cardiac monitoring: assess heart rate and rhythm, especially in patients with pre‑existing cardiac disease.
• Renal adjustment: reduce dose in moderate to severe renal impairment to avoid accumulation.
• Respiratory caution: monitor for signs of cholinergic crisis in patients with compromised lung function.
• Anticholinergic drugs: avoid concomitant use of strong anticholinergics that may diminish therapeutic effect.
• Pregnancy and lactation: use only if benefit outweighs potential risk, as safety data are limited.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Pyridostigmine bromide can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Anticholinergic agents: drugs such as atropine or scopolamine may counteract pyridostigmine’s effect.
• Other cholinesterase inhibitors: concurrent use can lead to excessive cholinergic activity.
• Beta‑blockers: may exacerbate bradycardia when combined with pyridostigmine.

Moderate Interactions (Monitor Closely)

• Beta‑2 agonists: may reduce the drug’s effectiveness on blood pressure regulation.
• Magnesium‑containing antacids: can diminish absorption of pyridostigmine.
• General anesthetics: neuromuscular blocking agents may have prolonged action; dosage may need adjustment.